{"id":348209,"date":"2025-08-25T14:00:15","date_gmt":"2025-08-25T14:00:15","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-edgewise-therapeutics\/"},"modified":"2025-08-25T14:00:15","modified_gmt":"2025-08-25T14:00:15","slug":"how-to-buy-edgewise-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/","title":{"rendered":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Edgewise Therapeutics (EWTX) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Edgewise Therapeutics (EWTX) hisselerine yat\u0131r\u0131m yapmay\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"Keskin kas hastal\u0131klar\u0131 tedavilerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Edgewise Therapeutics (EWTX), t\u0131bbi at\u0131l\u0131mlar\u0131n yat\u0131r\u0131m f\u0131rsatlar\u0131yla bulu\u015ftu\u011fu biyoteknoloji yenili\u011finin heyecan verici d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, kas distrofileri ve kardiyak durumlar i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor\u2014ila\u00e7 geli\u015ftirme alan\u0131n\u0131n y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc do\u011fas\u0131n\u0131 anlayan yat\u0131r\u0131mc\u0131lar i\u00e7in b\u00fcy\u00fcleyici bir se\u00e7enek.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin kas hastal\u0131klar\u0131 tedavilerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Edgewise Therapeutics (EWTX), t\u0131bbi at\u0131l\u0131mlar\u0131n yat\u0131r\u0131m f\u0131rsatlar\u0131yla bulu\u015ftu\u011fu biyoteknoloji yenili\u011finin heyecan verici d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, kas distrofileri ve kardiyak durumlar i\u00e7in devrim niteli\u011finde tedaviler geli\u015ftiriyor\u2014ila\u00e7 geli\u015ftirme alan\u0131n\u0131n y\u00fcksek riskli, y\u00fcksek \u00f6d\u00fcll\u00fc do\u011fas\u0131n\u0131 anlayan yat\u0131r\u0131mc\u0131lar i\u00e7in b\u00fcy\u00fcleyici bir se\u00e7enek."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Edgewise Therapeutics (EWTX) hisseleri NASDAQ borsas\u0131nda <strong>14,85 $<\/strong> seviyesinde i\u015flem g\u00f6rmektedir. \u015eirketin piyasa de\u011feri yakla\u015f\u0131k 1,47 milyar $ olup, \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip orta \u00f6l\u00e7ekli bir biyoteknoloji oyuncusu olarak konumlanmakta ancak ayn\u0131 zamanda \u00f6nemli volatilite riskleri ta\u015f\u0131maktad\u0131r.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 6 Kas\u0131m 2025<\/strong>, \u015firketin bir sonraki \u00e7eyrek kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131n yap\u0131laca\u011f\u0131 tarihtir. Tarihsel veriler, EWTX'in kazan\u00e7 duyurular\u0131 \u00e7evresinde kayda de\u011fer fiyat hareketleri ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u00d6nceki 2. \u00e7eyrek raporu 7 A\u011fustos 2025'te, \u015firketin EPS beklentilerini 0,08 $ a\u015fmas\u0131 sonras\u0131 %5 \u00f6n piyasa rallisi tetiklenmi\u015ftir (<a href=\"https:\/\/www.chartmill.com\/news\/EWTX\/Chartmill-32717-Edgewise-Therapeutics-Inc-NASDAQEWTX-Q2-2025-Earnings-EPS-Beat-Sparks-5-Pre-Market-Rally\">Chartmill<\/a>).<\/p> <h3>Kazan\u00e7 Etkisi Analizi:<\/h3> <ul> <li>7 A\u011fustos 2025: %5 \u00f6n piyasa art\u0131\u015f\u0131 (EPS s\u00fcrprizi: -0,34 $ vs beklenen -0,42 $)<\/li> <li>May\u0131s 2025: %12,93 ayl\u0131k d\u00fc\u015f\u00fc\u015f (b\u00fcy\u00fck kataliz\u00f6r yok)<\/li> <li>\u015eubat 2025: %6,60 d\u00fc\u015f\u00fc\u015f (genel piyasa bask\u0131lar\u0131)<\/li> <li>Kas\u0131m 2024: \u00d6nceki deneme verilerine kar\u0131\u015f\u0131k tepki<\/li> <\/ul> <p>Bu desen, olumlu klinik geli\u015fmeler ve kazan\u00e7 s\u00fcrprizlerinin an\u0131nda al\u0131m f\u0131rsatlar\u0131 yaratt\u0131\u011f\u0131n\u0131, haber olmayan d\u00f6nemlerin ise kademeli d\u00fc\u015f\u00fc\u015flere yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p> <h3>Alt\u0131 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h3> <p>EWTX, son alt\u0131 ayda dramatik volatilite ya\u015fam\u0131\u015f ve 2025 ba\u015f\u0131ndaki y\u00fcksek seviyelerden \u00f6nemli \u00f6l\u00e7\u00fcde d\u00fc\u015fm\u00fc\u015ft\u00fcr:<\/p> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ay<\/th> <th>Y\u00fcksek<\/th> <th>D\u00fc\u015f\u00fck<\/th> <th>Ayl\u0131k De\u011fi\u015fim<\/th> <th>\u00d6nemli Olaylar<\/th> <\/tr> <\/thead> <tbody> <tr> <td>Mart 2025<\/td> <td>30,04 $<\/td> <td>21,52 $<\/td> <td>%-15,93<\/td> <td>Genel piyasa d\u00fczeltmesi<\/td> <\/tr> <tr> <td>Nisan 2025<\/td> <td>22,47 $<\/td> <td>10,60 $<\/td> <td>%-25,45<\/td> <td>A\u011f\u0131r kurumsal sat\u0131\u015f<\/td> <\/tr> <tr> <td>May\u0131s 2025<\/td> <td>17,30 $<\/td> <td>13,63 $<\/td> <td>%-12,93<\/td> <td>Sessiz d\u00f6nem<\/td> <\/tr> <tr> <td>Haziran 2025<\/td> <td>16,30 $<\/td> <td>12,15 $<\/td> <td>%-8,19<\/td> <td>MESA deneme g\u00fcncellemeleri<\/td> <\/tr> <tr> <td>Temmuz 2025<\/td> <td>15,33 $<\/td> <td>12,51 $<\/td> <td>%+8,54<\/td> <td>Olumlu duygu d\u00f6n\u00fc\u015f\u00fc<\/td> <\/tr> <tr> <td>A\u011fustos 2025<\/td> <td>~15,00 $<\/td> <td>~14,00 $<\/td> <td>Stabilizasyon<\/td> <td>Kazan\u00e7 sonras\u0131 konsolidasyon<\/td> <\/tr> <\/tbody> <\/table> <p>Hisse senedi, Nisan sat\u0131\u015flar\u0131ndan sonra 12-14 $ aral\u0131\u011f\u0131nda destek bulmu\u015f olup, bu durum sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir taban olu\u015fturabilir (<a href=\"https:\/\/stockscan.io\/stocks\/EWTX\/price-history\">StockScan<\/a>).<\/p> <h3>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3> <p>Analist g\u00f6r\u00fc\u015fleri, klinik a\u015famadaki biyoteknolojinin y\u00fcksek riskli do\u011fas\u0131n\u0131 yans\u0131tarak EWTX'in gelece\u011fi hakk\u0131nda dramatik \u015fekilde farkl\u0131l\u0131k g\u00f6stermektedir:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu:<\/strong> 17-22 $ (klinik ilerlemeye dayal\u0131 \u0131l\u0131ml\u0131 toparlanma)<\/li> <li><strong>2026 Hedefi:<\/strong> 25-35 $ (Olas\u0131 Faz 3 deneme ba\u015flang\u0131\u00e7lar\u0131)<\/li> <li><strong>2028 Projeksiyonu:<\/strong> 40-60 $ (muhtemel ilk ticari onaylar)<\/li> <li><strong>2030 Vizyonu:<\/strong> 70-100+ $ (ba\u015far\u0131l\u0131 olursa yerle\u015fik ticari varl\u0131k)<\/li> <\/ul> <p>Bu geni\u015f aral\u0131k, ila\u00e7 geli\u015ftirme s\u00fcrecinin ikili do\u011fas\u0131ndan kaynaklanmaktad\u0131r\u2014ya tedaviler i\u015fe yarar ve milyarlar kazan\u0131l\u0131r ya da ba\u015far\u0131s\u0131z olur ve hisse \u00f6nemli \u00f6l\u00e7\u00fcde d\u00fc\u015fer (<a href=\"https:\/\/stockanalysis.com\/stocks\/ewtx\/forecast\/\">StockAnalysis<\/a>).<\/p> <p><strong>Karar: D\u0130KKATL\u0130 ALIM<\/strong> 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in. Mevcut fiyat, ba\u015far\u0131s\u0131zl\u0131k riskinin \u00e7o\u011funu fiyatlam\u0131\u015f gibi g\u00f6r\u00fcn\u00fcrken, klinik denemeler ba\u015far\u0131l\u0131 olursa \u00f6nemli bir yukar\u0131 potansiyel sunmaktad\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski:<\/strong> \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 klinik denemelerde ba\u015far\u0131s\u0131z olur<\/li> <li><strong>Mali Yakma:<\/strong> \u015eirket 2025 ilk yar\u0131 d\u00f6neminde 76,91 milyon $ zarar bildirdi (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-ewtx\/edgewise-therapeutics\/news\/will-edgewise-therapeutics-ewtx-rising-losses-reshape-its-lo\">Simply Wall St<\/a>)<\/li> <li><strong>Hisse Seyrelme Riski:<\/strong> Karl\u0131l\u0131\u011fa ula\u015fmadan \u00f6nce ek sermaye art\u0131r\u0131m\u0131 gerekebilir<\/li> <li><strong>Reg\u00fclasyon Engelleri:<\/strong> FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemezli\u011fini koruyor<\/li> <li><strong>Rekabet:<\/strong> Benzer tedaviler geli\u015ftiren daha b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler:<\/h3> <ul> <li><strong>MESA Deneme Ba\u015far\u0131s\u0131:<\/strong> S\u00fcrd\u00fcr\u00fclebilir etkinli\u011fi g\u00f6steren olumlu uzatma verileri<\/li> <li><strong>EDG-7500 \u0130lerlemesi:<\/strong> Faz 2 kardiyak verilerinin 2025 sonlar\u0131nda beklenmesi<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131:<\/strong> Kas distrofisi tedavi pazar\u0131 y\u0131ll\u0131k %8 b\u00fcy\u00fcyor<\/li> <li><strong>Analist Deste\u011fi:<\/strong> 11 analistin ortalama 40,55 $ fiyat hedefi (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/EWTX\/forecast\/\">MarketBeat<\/a>)<\/li> <li><strong>K\u0131sa Pozisyon \u0130lgi D\u00fczeyi:<\/strong> D\u00fc\u015f\u00fck k\u0131sa pozisyon, s\u0131n\u0131rl\u0131 d\u00fc\u015f\u00fc\u015f beklentisi g\u00f6steriyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 EWTX gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Uyar\u0131lar Kurun:<\/strong> Kas\u0131m kazan\u00e7lar\u0131n\u0131 ve klinik deneme duyurular\u0131n\u0131 takip edin<\/li> <li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin:<\/strong> Yat\u0131r\u0131m \u00f6ncesi zarar tolerans\u0131n\u0131z\u0131 bilin<\/li> <\/ol> <p><em>Mizahi deneyimli tavsiye: \"EWTX ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici potansiyel ama beklenmedik deneylerin y\u00fcz\u00fcn\u00fcze patlamas\u0131na haz\u0131rl\u0131kl\u0131 olun!\"<\/em><\/p> <h2>\u2705 Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir i\u015flem platformu se\u00e7in<\/td> <td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td> <td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td> <\/tr> <tr> <td>3<\/td> <td>Fon yat\u0131r\u0131n<\/td> <td>Tamamen riske atabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>\"EWTX\" aramas\u0131 yap\u0131n<\/td> <td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>6<\/td> <td>\u0130nceleyin ve onaylay\u0131n<\/td> <td>\u0130\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td> <\/tr> <tr> <td>7<\/td> <td>Pozisyonu izleyin<\/td> <td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td> <\/tr> <\/tbody> <\/table> <h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'\u0131n Cazibesi<\/h3> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, EWTX ve di\u011fer biyoteknoloji hisseleriyle stratejileri test etmek i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito<\/strong>: Sadece 5 $ ile ger\u00e7ek piyasa ko\u015fullar\u0131nda pratik yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: KYC s\u00fcreci sadece bir belge ile dakikalar i\u00e7inde tamamlan\u0131r<\/li> <li><strong>Esnek para \u00e7ekme<\/strong>: Kripto paralar ve e-c\u00fczdanlar dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong>: Pocket Option blogu s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri sa\u011flar<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Edgewise Therapeutics: Kas Hastal\u0131klar\u0131 Tedavisinde \u00d6nc\u00fc<\/h2> <p>Edgewise Therapeutics, kas distrofisi tedavi geli\u015ftirmede \u00f6n saflarda yer almaktad\u0131r. \u015eirketin \u00f6nc\u00fc ila\u00e7 aday\u0131 sevasemten (EDG-5506), kas liflerini kas\u0131lma kaynakl\u0131 hasardan korumaya y\u00f6nelik yenilik\u00e7i bir yakla\u015f\u0131m\u0131 temsil eder\u2014Duchenne ve Becker kas distrofisi gibi durumlar\u0131n tedavisinde temel bir at\u0131l\u0131m (<a href=\"https:\/\/edgewisetx.com\/disease-areas\/muscular-dystrophy\/\">Edgewise Therapeutics<\/a>).<\/p> <p>\u015eirketin ara\u015ft\u0131rmalar\u0131, DMD hastalar\u0131ndan al\u0131nan kas doku \u00f6rneklerinin incelenmesiyle ba\u015flam\u0131\u015f ve bilim insanlar\u0131 belirli kas lifi tiplerinin tercihli olarak dejenerasyona u\u011frad\u0131\u011f\u0131n\u0131 ke\u015ffetmi\u015ftir. Bu i\u00e7g\u00f6r\u00fc, molek\u00fcler yollar yerine kas\u0131 bir organ sistemi olarak hedef alan benzersiz platformlar\u0131na yol a\u00e7m\u0131\u015ft\u0131r.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Edgewise CEO'su Kevin Koch, daha \u00f6nce FDA onayl\u0131 ve y\u0131ll\u0131k 2 milyar $ \u00fczerinde gelir getiren spinal m\u00fcsk\u00fcler atrofi i\u00e7in ilk tedavi olan Spinraza'n\u0131n geli\u015ftirilmesine katk\u0131da bulunmu\u015ftur. Bilimsel ke\u015fifleri ticari ba\u015far\u0131lara d\u00f6n\u00fc\u015ft\u00fcrme deneyimi, EWTX'in geli\u015fim yolculu\u011funda de\u011ferli bir liderlik sa\u011flamaktad\u0131r.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Edgewise Therapeutics (EWTX) hisseleri NASDAQ borsas\u0131nda <strong>14,85 $<\/strong> seviyesinde i\u015flem g\u00f6rmektedir. \u015eirketin piyasa de\u011feri yakla\u015f\u0131k 1,47 milyar $ olup, \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip orta \u00f6l\u00e7ekli bir biyoteknoloji oyuncusu olarak konumlanmakta ancak ayn\u0131 zamanda \u00f6nemli volatilite riskleri ta\u015f\u0131maktad\u0131r.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 6 Kas\u0131m 2025<\/strong>, \u015firketin bir sonraki \u00e7eyrek kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131n yap\u0131laca\u011f\u0131 tarihtir. Tarihsel veriler, EWTX&#8217;in kazan\u00e7 duyurular\u0131 \u00e7evresinde kayda de\u011fer fiyat hareketleri ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u00d6nceki 2. \u00e7eyrek raporu 7 A\u011fustos 2025&#8217;te, \u015firketin EPS beklentilerini 0,08 $ a\u015fmas\u0131 sonras\u0131 %5 \u00f6n piyasa rallisi tetiklenmi\u015ftir (<a href=\"https:\/\/www.chartmill.com\/news\/EWTX\/Chartmill-32717-Edgewise-Therapeutics-Inc-NASDAQEWTX-Q2-2025-Earnings-EPS-Beat-Sparks-5-Pre-Market-Rally\">Chartmill<\/a>).<\/p>\n<h3>Kazan\u00e7 Etkisi Analizi:<\/h3>\n<ul>\n<li>7 A\u011fustos 2025: %5 \u00f6n piyasa art\u0131\u015f\u0131 (EPS s\u00fcrprizi: -0,34 $ vs beklenen -0,42 $)<\/li>\n<li>May\u0131s 2025: %12,93 ayl\u0131k d\u00fc\u015f\u00fc\u015f (b\u00fcy\u00fck kataliz\u00f6r yok)<\/li>\n<li>\u015eubat 2025: %6,60 d\u00fc\u015f\u00fc\u015f (genel piyasa bask\u0131lar\u0131)<\/li>\n<li>Kas\u0131m 2024: \u00d6nceki deneme verilerine kar\u0131\u015f\u0131k tepki<\/li>\n<\/ul>\n<p>Bu desen, olumlu klinik geli\u015fmeler ve kazan\u00e7 s\u00fcrprizlerinin an\u0131nda al\u0131m f\u0131rsatlar\u0131 yaratt\u0131\u011f\u0131n\u0131, haber olmayan d\u00f6nemlerin ise kademeli d\u00fc\u015f\u00fc\u015flere yol a\u00e7t\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n<h3>Alt\u0131 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h3>\n<p>EWTX, son alt\u0131 ayda dramatik volatilite ya\u015fam\u0131\u015f ve 2025 ba\u015f\u0131ndaki y\u00fcksek seviyelerden \u00f6nemli \u00f6l\u00e7\u00fcde d\u00fc\u015fm\u00fc\u015ft\u00fcr:<\/p>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Y\u00fcksek<\/th>\n<th>D\u00fc\u015f\u00fck<\/th>\n<th>Ayl\u0131k De\u011fi\u015fim<\/th>\n<th>\u00d6nemli Olaylar<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>30,04 $<\/td>\n<td>21,52 $<\/td>\n<td>%-15,93<\/td>\n<td>Genel piyasa d\u00fczeltmesi<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>22,47 $<\/td>\n<td>10,60 $<\/td>\n<td>%-25,45<\/td>\n<td>A\u011f\u0131r kurumsal sat\u0131\u015f<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>17,30 $<\/td>\n<td>13,63 $<\/td>\n<td>%-12,93<\/td>\n<td>Sessiz d\u00f6nem<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>16,30 $<\/td>\n<td>12,15 $<\/td>\n<td>%-8,19<\/td>\n<td>MESA deneme g\u00fcncellemeleri<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>15,33 $<\/td>\n<td>12,51 $<\/td>\n<td>%+8,54<\/td>\n<td>Olumlu duygu d\u00f6n\u00fc\u015f\u00fc<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>~15,00 $<\/td>\n<td>~14,00 $<\/td>\n<td>Stabilizasyon<\/td>\n<td>Kazan\u00e7 sonras\u0131 konsolidasyon<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse senedi, Nisan sat\u0131\u015flar\u0131ndan sonra 12-14 $ aral\u0131\u011f\u0131nda destek bulmu\u015f olup, bu durum sab\u0131rl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir taban olu\u015fturabilir (<a href=\"https:\/\/stockscan.io\/stocks\/EWTX\/price-history\">StockScan<\/a>).<\/p>\n<h3>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3>\n<p>Analist g\u00f6r\u00fc\u015fleri, klinik a\u015famadaki biyoteknolojinin y\u00fcksek riskli do\u011fas\u0131n\u0131 yans\u0131tarak EWTX&#8217;in gelece\u011fi hakk\u0131nda dramatik \u015fekilde farkl\u0131l\u0131k g\u00f6stermektedir:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu:<\/strong> 17-22 $ (klinik ilerlemeye dayal\u0131 \u0131l\u0131ml\u0131 toparlanma)<\/li>\n<li><strong>2026 Hedefi:<\/strong> 25-35 $ (Olas\u0131 Faz 3 deneme ba\u015flang\u0131\u00e7lar\u0131)<\/li>\n<li><strong>2028 Projeksiyonu:<\/strong> 40-60 $ (muhtemel ilk ticari onaylar)<\/li>\n<li><strong>2030 Vizyonu:<\/strong> 70-100+ $ (ba\u015far\u0131l\u0131 olursa yerle\u015fik ticari varl\u0131k)<\/li>\n<\/ul>\n<p>Bu geni\u015f aral\u0131k, ila\u00e7 geli\u015ftirme s\u00fcrecinin ikili do\u011fas\u0131ndan kaynaklanmaktad\u0131r\u2014ya tedaviler i\u015fe yarar ve milyarlar kazan\u0131l\u0131r ya da ba\u015far\u0131s\u0131z olur ve hisse \u00f6nemli \u00f6l\u00e7\u00fcde d\u00fc\u015fer (<a href=\"https:\/\/stockanalysis.com\/stocks\/ewtx\/forecast\/\">StockAnalysis<\/a>).<\/p>\n<p><strong>Karar: D\u0130KKATL\u0130 ALIM<\/strong> 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in. Mevcut fiyat, ba\u015far\u0131s\u0131zl\u0131k riskinin \u00e7o\u011funu fiyatlam\u0131\u015f gibi g\u00f6r\u00fcn\u00fcrken, klinik denemeler ba\u015far\u0131l\u0131 olursa \u00f6nemli bir yukar\u0131 potansiyel sunmaktad\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski:<\/strong> \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 klinik denemelerde ba\u015far\u0131s\u0131z olur<\/li>\n<li><strong>Mali Yakma:<\/strong> \u015eirket 2025 ilk yar\u0131 d\u00f6neminde 76,91 milyon $ zarar bildirdi (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-ewtx\/edgewise-therapeutics\/news\/will-edgewise-therapeutics-ewtx-rising-losses-reshape-its-lo\">Simply Wall St<\/a>)<\/li>\n<li><strong>Hisse Seyrelme Riski:<\/strong> Karl\u0131l\u0131\u011fa ula\u015fmadan \u00f6nce ek sermaye art\u0131r\u0131m\u0131 gerekebilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri:<\/strong> FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemezli\u011fini koruyor<\/li>\n<li><strong>Rekabet:<\/strong> Benzer tedaviler geli\u015ftiren daha b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu Kataliz\u00f6rler:<\/h3>\n<ul>\n<li><strong>MESA Deneme Ba\u015far\u0131s\u0131:<\/strong> S\u00fcrd\u00fcr\u00fclebilir etkinli\u011fi g\u00f6steren olumlu uzatma verileri<\/li>\n<li><strong>EDG-7500 \u0130lerlemesi:<\/strong> Faz 2 kardiyak verilerinin 2025 sonlar\u0131nda beklenmesi<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131:<\/strong> Kas distrofisi tedavi pazar\u0131 y\u0131ll\u0131k %8 b\u00fcy\u00fcyor<\/li>\n<li><strong>Analist Deste\u011fi:<\/strong> 11 analistin ortalama 40,55 $ fiyat hedefi (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/EWTX\/forecast\/\">MarketBeat<\/a>)<\/li>\n<li><strong>K\u0131sa Pozisyon \u0130lgi D\u00fczeyi:<\/strong> D\u00fc\u015f\u00fck k\u0131sa pozisyon, s\u0131n\u0131rl\u0131 d\u00fc\u015f\u00fc\u015f beklentisi g\u00f6steriyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 EWTX gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Uyar\u0131lar Kurun:<\/strong> Kas\u0131m kazan\u00e7lar\u0131n\u0131 ve klinik deneme duyurular\u0131n\u0131 takip edin<\/li>\n<li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin:<\/strong> Yat\u0131r\u0131m \u00f6ncesi zarar tolerans\u0131n\u0131z\u0131 bilin<\/li>\n<\/ol>\n<p><em>Mizahi deneyimli tavsiye: &#8220;EWTX ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici potansiyel ama beklenmedik deneylerin y\u00fcz\u00fcn\u00fcze patlamas\u0131na haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/em><\/p>\n<h2>\u2705 Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Tamamen riske atabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;EWTX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;\u0131n Cazibesi<\/h3>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, EWTX ve di\u011fer biyoteknoloji hisseleriyle stratejileri test etmek i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito<\/strong>: Sadece 5 $ ile ger\u00e7ek piyasa ko\u015fullar\u0131nda pratik yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: KYC s\u00fcreci sadece bir belge ile dakikalar i\u00e7inde tamamlan\u0131r<\/li>\n<li><strong>Esnek para \u00e7ekme<\/strong>: Kripto paralar ve e-c\u00fczdanlar dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong>: Pocket Option blogu s\u00fcrekli piyasa i\u00e7g\u00f6r\u00fcleri sa\u011flar<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Edgewise Therapeutics: Kas Hastal\u0131klar\u0131 Tedavisinde \u00d6nc\u00fc<\/h2>\n<p>Edgewise Therapeutics, kas distrofisi tedavi geli\u015ftirmede \u00f6n saflarda yer almaktad\u0131r. \u015eirketin \u00f6nc\u00fc ila\u00e7 aday\u0131 sevasemten (EDG-5506), kas liflerini kas\u0131lma kaynakl\u0131 hasardan korumaya y\u00f6nelik yenilik\u00e7i bir yakla\u015f\u0131m\u0131 temsil eder\u2014Duchenne ve Becker kas distrofisi gibi durumlar\u0131n tedavisinde temel bir at\u0131l\u0131m (<a href=\"https:\/\/edgewisetx.com\/disease-areas\/muscular-dystrophy\/\">Edgewise Therapeutics<\/a>).<\/p>\n<p>\u015eirketin ara\u015ft\u0131rmalar\u0131, DMD hastalar\u0131ndan al\u0131nan kas doku \u00f6rneklerinin incelenmesiyle ba\u015flam\u0131\u015f ve bilim insanlar\u0131 belirli kas lifi tiplerinin tercihli olarak dejenerasyona u\u011frad\u0131\u011f\u0131n\u0131 ke\u015ffetmi\u015ftir. Bu i\u00e7g\u00f6r\u00fc, molek\u00fcler yollar yerine kas\u0131 bir organ sistemi olarak hedef alan benzersiz platformlar\u0131na yol a\u00e7m\u0131\u015ft\u0131r.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Edgewise CEO&#8217;su Kevin Koch, daha \u00f6nce FDA onayl\u0131 ve y\u0131ll\u0131k 2 milyar $ \u00fczerinde gelir getiren spinal m\u00fcsk\u00fcler atrofi i\u00e7in ilk tedavi olan Spinraza&#8217;n\u0131n geli\u015ftirilmesine katk\u0131da bulunmu\u015ftur. Bilimsel ke\u015fifleri ticari ba\u015far\u0131lara d\u00f6n\u00fc\u015ft\u00fcrme deneyimi, EWTX&#8217;in geli\u015fim yolculu\u011funda de\u011ferli bir liderlik sa\u011flamaktad\u0131r.<\/p>\n"},"faq":[{"question":"Edgewise Therapeutics (EWTX) hisseleri nereden al\u0131nabilir?","answer":"EWTX hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Edgewise Therapeutics hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k, finansal kay\u0131plar, hisse seyrelmesi, reg\u00fclasyon engelleri ve rekabet yer almaktad\u0131r."},{"question":"EWTX hisseleri i\u00e7in fiyat tahminleri nelerdir?","answer":"Analistlere g\u00f6re 2025 sonunda 17-22 $, 2026'da 25-35 $, 2028'de 40-60 $ ve 2030'da 70-100+ $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar EWTX hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyet ortalamas\u0131 yaparak, uyar\u0131lar kurarak ve bir \u00e7\u0131k\u0131\u015f stratejisi belirleyerek yat\u0131r\u0131m yapman\u0131z \u00f6nerilir."},{"question":"Edgewise Therapeutics'in \u00f6ne \u00e7\u0131kan ila\u00e7 aday\u0131 nedir?","answer":"\u015eirketin \u00f6nc\u00fc ilac\u0131 sevasemten (EDG-5506), kas liflerini kas\u0131lma kaynakl\u0131 hasardan koruyan yenilik\u00e7i bir tedavidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Edgewise Therapeutics (EWTX) hisseleri nereden al\u0131nabilir?","answer":"EWTX hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Edgewise Therapeutics hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k, finansal kay\u0131plar, hisse seyrelmesi, reg\u00fclasyon engelleri ve rekabet yer almaktad\u0131r."},{"question":"EWTX hisseleri i\u00e7in fiyat tahminleri nelerdir?","answer":"Analistlere g\u00f6re 2025 sonunda 17-22 $, 2026'da 25-35 $, 2028'de 40-60 $ ve 2030'da 70-100+ $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayanlar EWTX hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyet ortalamas\u0131 yaparak, uyar\u0131lar kurarak ve bir \u00e7\u0131k\u0131\u015f stratejisi belirleyerek yat\u0131r\u0131m yapman\u0131z \u00f6nerilir."},{"question":"Edgewise Therapeutics'in \u00f6ne \u00e7\u0131kan ila\u00e7 aday\u0131 nedir?","answer":"\u015eirketin \u00f6nc\u00fc ilac\u0131 sevasemten (EDG-5506), kas liflerini kas\u0131lma kaynakl\u0131 hasardan koruyan yenilik\u00e7i bir tedavidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T14:00:15+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T14:00:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\",\"name\":\"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-25T14:00:15+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T14:00:15+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T14:00:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/","name":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-25T14:00:15+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Edgewise Therapeutics, Inc. (EWTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Edgewise Therapeutics, Inc. (EWTX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":348213,"slug":"how-to-buy-edgewise-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Edgewise Therapeutics, Inc. (EWTX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Edgewise Therapeutics, Inc. (EWTX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348208,"slug":"how-to-buy-edgewise-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Edgewise Therapeutics, Inc. (EWTX) - Investimento em a\u00e7\u00f5es da Edgewise Therapeutics, Inc. (EWTX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-edgewise-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=348209"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348209\/revisions"}],"predecessor-version":[{"id":348212,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/348209\/revisions\/348212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=348209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=348209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=348209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}